ReviewEndocrinology, diabetes & metabolism2026
The Impact of Diabetes on Breast Cancer Development in Women: An Integrative Review.
Review in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIncreasing epidemiological evidence suggests that diabetes is associated with a modest but significant elevation in breast cancer risk, as well as poorer clinical outcomes following diagnosis. This integrative review critically synthesizes current epidemiological, biological and clinical evidence to elucidate the role of diabetes in breast cancer development and progression among women.
methodsWe conducted a structured literature search (2010-2025) to identify original studies examining the relationship between diabetes and breast cancer risk and outcomes. English-language human studies were included. Titles, abstracts and full texts were screened against predefined criteria, and relevant data were extracted and synthesized narratively.
resultsStudies indicate that women with diabetes experience an increased incidence of breast cancer, with stronger associations observed in postmenopausal populations, and partial attenuation of risk following adjustment for obesity, highlighting both shared and independent metabolic contributions. Mechanistically, chronic hyperinsulinemia, altered insulin-like growth factor signalling, low-grade systemic inflammation, oxidative stress and oestrogen-metabolic crosstalk are frequently proposed as biologically plausible pathways through which diabetes may influence breast carcinogenesis, particularly in hormone-receptor-positive tumours. Clinically, diabetes has been linked to delayed diagnosis, increased treatment-related complications, and higher breast cancer-specific mortality, underscoring the need for integrated metabolic and oncologic care.
conclusionDiabetes mellitus, particularly type 2 diabetes, is consistently associated in observational studies with a small increment in breast cancer risk and a more clearly adverse impact on survival. Mechanistic and translational evidence supports biologically plausible pathways linking metabolic dysregulation to tumour initiation, progression and treatment tolerance, but definitive causal effects remain uncertain. Medication and biomarker-based research and practice should be incorporated in metabolic-oncologic care and research to enhance prevention and outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.